Joan Montaner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2296697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Ultrasound-Enhanced Systemic Thrombolysis for Acute Ischemic Stroke. New England Journal of Medicine, 2004, 351, 2170-2178.	27.0	1,006
2	European Stroke Organisation (ESO) Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. International Journal of Stroke, 2014, 9, 840-855.	5.9	638
3	Matrix Metalloproteinase-9 Pretreatment Level Predicts Intracranial Hemorrhagic Complications After Thrombolysis in Human Stroke. Circulation, 2003, 107, 598-603.	1.6	494
4	MMP-9–Positive Neutrophil Infiltration Is Associated to Blood–Brain Barrier Breakdown and Basal Lamina Type IV Collagen Degradation During Hemorrhagic Transformation After Human Ischemic Stroke. Stroke, 2008, 39, 1121-1126.	2.0	466
5	Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE Collaboration): a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2012, 11, 951-962.	10.2	445
6	Microbubble Administration Accelerates Clot Lysis During Continuous 2-MHz Ultrasound Monitoring in Stroke Patients Treated With Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 425-429.	2.0	431
7	Increased Brain Expression of Matrix Metalloproteinase-9 After Ischemic and Hemorrhagic Human Stroke. Stroke, 2006, 37, 1399-1406.	2.0	382
8	Tandem Internal Carotid Artery/Middle Cerebral Artery Occlusion. Stroke, 2006, 37, 2301-2305.	2.0	350
9	Matrix Metalloproteinase Expression After Human Cardioembolic Stroke. Stroke, 2001, 32, 1759-1766.	2.0	327
10	Diagnosis of Stroke-Associated Pneumonia. Stroke, 2015, 46, 2335-2340.	2.0	275
11	Etiologic Diagnosis of Ischemic Stroke Subtypes With Plasma Biomarkers. Stroke, 2008, 39, 2280-2287.	2.0	264
12	Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Annals of Neurology, 2010, 68, 934-943.	5.3	241
13	Timing of Spontaneous Recanalization and Risk of Hemorrhagic Transformation in Acute Cardioembolic Stroke. Stroke, 2001, 32, 1079-1084.	2.0	235
14	Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator–Treated Patients. Stroke, 2003, 34, 1235-1240.	2.0	235
15	Meta-analysis of Genome-wide Association Studies Identifies 1q22 as a Susceptibility Locus for Intracerebral Hemorrhage. American Journal of Human Genetics, 2014, 94, 511-521.	6.2	235
16	Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurology, The, 2018, 17, 885-894.	10.2	229
17	Thrombolysis-Related Hemorrhagic Infarction. Stroke, 2002, 33, 1551-1556.	2.0	224
18	Tissue Plasminogen Activator Promotes Matrix Metalloproteinase-9 Upregulation After Focal Cerebral Ischemia. Stroke, 2005, 36, 1954-1959.	2.0	215

#	Article	IF	CITATIONS
19	Higher Risk of Further Vascular Events Among Transient Ischemic Attack Patients With Diffusion-Weighted Imaging Acute Ischemic Lesions. Stroke, 2004, 35, 2313-2319.	2.0	210
20	Intra-Arterial Bone Marrow Mononuclear Cells in Ischemic Stroke. Stroke, 2012, 43, 2242-2244.	2.0	208
21	Patterns and Predictors of Early Risk of Recurrence After Transient Ischemic Attack With Respect to Etiologic Subtypes. Stroke, 2007, 38, 3225-3229.	2.0	204
22	Statin Therapy and Outcome After Ischemic Stroke. Stroke, 2013, 44, 448-456.	2.0	200
23	Temporal Profile of Matrix Metalloproteinases and Their Inhibitors After Spontaneous Intracerebral Hemorrhage. Stroke, 2004, 35, 1316-1322.	2.0	199
24	Predictors of Early Arterial Reocclusion After Tissue Plasminogen Activator-Induced Recanalization in Acute Ischemic Stroke. Stroke, 2005, 36, 1452-1456.	2.0	199
25	Progression and Clinical Recurrence of Symptomatic Middle Cerebral Artery Stenosis. Stroke, 2001, 32, 2898-2904.	2.0	198
26	Acute Hyperglycemia State Is Associated With Lower tPA-Induced Recanalization Rates in Stroke Patients. Stroke, 2005, 36, 1705-1709.	2.0	198
27	Searching for Atrial Fibrillation Poststroke. Circulation, 2019, 140, 1834-1850.	1.6	184
28	Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds. Neurology, 2017, 89, 820-829.	1.1	180
29	Differential Pattern of Tissue Plasminogen Activator–Induced Proximal Middle Cerebral Artery Recanalization Among Stroke Subtypes. Stroke, 2004, 35, 486-490.	2.0	178
30	Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurology, The, 2017, 16, 217-226.	10.2	176
31	Consensus statement for diagnosis of subcortical small vessel disease. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 6-25.	4.3	173
32	VEGF-Induced BBB Permeability is Associated with an MMP-9 Activity Increase in Cerebral ischemia: Both Effects Decreased by ANG-1. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, 1491-1504.	4.3	172
33	C-Reactive Protein Predicts Further Ischemic Events in First-Ever Transient Ischemic Attack or Stroke Patients With Intracranial Large-Artery Occlusive Disease. Stroke, 2003, 34, 2463-2468.	2.0	171
34	Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke. Nature Reviews Neurology, 2020, 16, 247-264.	10.1	167
35	Prediction of Early Neurological Deterioration Using Diffusion- and Perfusion-Weighted Imaging in Hyperacute Middle Cerebral Artery Ischemic Stroke. Stroke, 2002, 33, 2197-2205.	2.0	160
36	Matrix metalloproteinase—9 concentration after spontaneous intracerebral hemorrhage. Journal of Neurosurgery, 2003, 99, 65-70.	1.6	156

#	Article	IF	CITATIONS
37	Time Course of Tissue Plasminogen Activator–Induced Recanalization in Acute Cardioembolic Stroke. Stroke, 2001, 32, 2821-2827.	2.0	152
38	A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke. Stroke, 2005, 36, 1415-1420.	2.0	146
39	Astrocytic Induction of Matrix Metalloproteinase-9 and Edema in Brain Hemorrhage. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 460-468.	4.3	145
40	Impact of Admission Hyperglycemia on Stroke Outcome After Thrombolysis. Stroke, 2004, 35, 2493-2498.	2.0	138
41	Metalloproteinase and stroke infarct size: role for antiâ€inflammatory treatment?. Annals of the New York Academy of Sciences, 2010, 1207, 123-133.	3.8	133
42	Stroke-induced immunodepression and dysphagia independently predict stroke-associated pneumonia – The PREDICT study. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 3671-3682.	4.3	133
43	B-Type Natriuretic Peptides Help in Cardioembolic Stroke Diagnosis. Stroke, 2015, 46, 1187-1195.	2.0	132
44	Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2016, 15, 695-707.	10.2	130
45	Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window Using Multimodal Transcranial Doppler/MRI Selection Protocol. Stroke, 2005, 36, 602-606.	2.0	128
46	Break in the Stroke Chain of Survival due to COVID-19. Stroke, 2020, 51, 2307-2314.	2.0	125
47	Elevated Serum S100B Levels Indicate a Higher Risk of Hemorrhagic Transformation After Thrombolytic Therapy in Acute Stroke. Stroke, 2007, 38, 2491-2495.	2.0	124
48	Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurology, The, 2014, 13, 419-428.	10.2	124
49	How Is Pneumonia Diagnosed in Clinical Stroke Research?. Stroke, 2015, 46, 1202-1209.	2.0	124
50	Temporal Profile of Recanalization After Intravenous Tissue Plasminogen Activator. Stroke, 2006, 37, 1000-1004.	2.0	119
51	Tissue plasminogen activator (t-PA) promotes neutrophil degranulation and MMP-9 release. Journal of Leukocyte Biology, 2008, 84, 207-214.	3.3	118
52	Increased intranuclear matrix metalloproteinase activity in neurons interferes with oxidative DNA repair in focal cerebral ischemia. Journal of Neurochemistry, 2010, 112, 134-149.	3.9	118
53	EuroHYP-1: European Multicenter, Randomized, Phase III Clinical Trial of Therapeutic Hypothermia plus Best Medical Treatment vs. Best Medical Treatment Alone for Acute Ischemic Stroke. International Journal of Stroke, 2014, 9, 642-645.	5.9	118
54	Neuronal Production of Lipocalin-2 as a Help-Me Signal for Glial Activation. Stroke, 2014, 45, 2085-2092.	2.0	117

#	Article	IF	CITATIONS
55	Impaired Cerebrovascular Reactivity as a Risk Marker for First-Ever Lacunar Infarction. Stroke, 1999, 30, 2296-2301.	2.0	116
56	Plasmatic Level of Neuroinflammatory Markers Predict the Extent of Diffusion-Weighted Image Lesions in Hyperacute Stroke. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 1403-1407.	4.3	116
57	Admission Fibrinolytic Profile Is Associated With Symptomatic Hemorrhagic Transformation in Stroke Patients Treated With Tissue Plasminogen Activator. Stroke, 2004, 35, 2123-2127.	2.0	111
58	Immunomodulation by interleukin-33 is protective in stroke through modulation of inflammation. Brain, Behavior, and Immunity, 2015, 49, 322-336.	4.1	107
59	Sequential Amyloid-β Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. Journal of Biological Chemistry, 2015, 290, 15078-15091.	3.4	107
60	Blood Biomarkers for the Early Diagnosis of Stroke. Stroke, 2017, 48, 2419-2425.	2.0	107
61	Common variation in <i>COL4A1/COL4A2</i> is associated with sporadic cerebral small vessel disease. Neurology, 2015, 84, 918-926.	1.1	106
62	Protective Effects of Endothelial Progenitor Cell-Derived Extracellular Mitochondria in Brain Endothelium. Stem Cells, 2018, 36, 1404-1410.	3.2	106
63	Hyperfibrinolysis increases blood–brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. Blood, 2016, 128, 2423-2434.	1.4	104
64	A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis, 2011, 216, 205-211.	0.8	103
65	Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: A systematic review and meta-analysis. Journal of Neuroimmunology, 2014, 274, 215-224.	2.3	100
66	Thrombin-Activable Fibrinolysis Inhibitor Levels in the Acute Phase of Ischemic Stroke. Stroke, 2003, 34, 1038-1040.	2.0	96
67	Inhibition of 12/15â€lipoxygenase as therapeutic strategy to treat stroke. Annals of Neurology, 2013, 73, 129-135.	5.3	96
68	Ischemic stroke outcome: A review of the influence of post-stroke complications within the different scenarios of stroke care. European Journal of Internal Medicine, 2016, 29, 9-21.	2.2	94
69	Vascular MMP-9/TIMP-2 and Neuronal MMP-10 Up-Regulation in Human Brain after Stroke: A Combined Laser Microdissection and Protein Array Study. Journal of Proteome Research, 2009, 8, 3191-3197.	3.7	93
70	Factors Secreted by Endothelial Progenitor Cells Enhance Neurorepair Responses after Cerebral Ischemia in Mice. PLoS ONE, 2013, 8, e73244.	2.5	93
71	Poststroke C-Reactive Protein Is a Powerful Prognostic Tool Among Candidates for Thrombolysis. Stroke, 2006, 37, 1205-1210.	2.0	90
72	Brain Extracellular Fluid Protein Changes in Acute Stroke Patients. Journal of Proteome Research, 2011, 10, 1043-1051.	3.7	90

#	Article	IF	CITATIONS
73	Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis, 2006, 187, 161-169.	0.8	89
74	Progression of Symptomatic Intracranial Large Artery Atherosclerosis Is Associated With a Proinflammatory State and Impaired Fibrinolysis. Stroke, 2008, 39, 1456-1463.	2.0	89
75	Meta-analysis in more than 17,900 cases of ischemic stroke reveals a novel association at 12q24.12. Neurology, 2014, 83, 678-685.	1.1	89
76	Heritability Estimates Identify a Substantial Genetic Contribution to Risk and Outcome of Intracerebral Hemorrhage. Stroke, 2013, 44, 1578-1583.	2.0	88
77	The choroid plexus is a key cerebral invasion route for T cells after stroke. Acta Neuropathologica, 2017, 134, 851-868.	7.7	87
78	Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thrombosis and Haemostasis, 2004, 91, 1146-1151.	3.4	86
79	<i>TTC7B</i> Emerges as a Novel Risk Factor for Ischemic Stroke Through the Convergence of Several Genome-Wide Approaches. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 1061-1072.	4.3	86
80	Oxidative Stress After Thrombolysis-Induced Reperfusion in Human Stroke. Stroke, 2010, 41, 653-660.	2.0	83
81	B-type natriuretic peptides and mortality after stroke. Neurology, 2013, 81, 1976-1985.	1.1	82
82	Neuroinflammatory biomarkers: From stroke diagnosis and prognosis to therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 411-424.	3.8	79
83	Blood/Brain Biomarkers of Inflammation After Stroke and Their Association With Outcome: From C-Reactive Protein to Damage-Associated Molecular Patterns. Neurotherapeutics, 2016, 13, 671-684.	4.4	78
84	Moderate and severe traumatic brain injury induce early overexpression of systemic and brain gelatinases. Intensive Care Medicine, 2008, 34, 1384-1392.	8.2	77
85	ADAMTS proteoglycanases in the physiological and pathological central nervous system. Journal of Neuroinflammation, 2013, 10, 133.	7.2	77
86	Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878934.	3.5	77
87	The Association of the 4q25 Susceptibility Variant for Atrial Fibrillation With Stroke Is Limited to Stroke of Cardioembolic Etiology. Stroke, 2010, 41, 1850-1857.	2.0	76
88	Prior Statin Use May Be Associated With Improved Stroke Outcome After Tissue Plasminogen Activator. Stroke, 2007, 38, 1076-1078.	2.0	75
89	MMPâ€2/MMPâ€9 Plasma Level and Brain Expression in Cerebral Amyloid Angiopathyâ€Associated Hemorrhagic Stroke. Brain Pathology, 2012, 22, 133-141.	4.1	73
90	Short-Term Blood Pressure Variability Relates to the Presence of Subclinical Brain Small Vessel Disease in Primary Hypertension. Hypertension, 2015, 66, 634-640.	2.7	72

#	Article	IF	CITATIONS
91	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. Journal of Alzheimer's Disease, 2015, 48, 711-720.	2.6	71
92	Evidence for the efficacy of statins in animal stroke models: a metaâ€analysis. Journal of Neurochemistry, 2012, 122, 233-243.	3.9	70
93	Mobilization, endothelial differentiation and functional capacity of endothelial progenitor cells after ischemic stroke. Microvascular Research, 2010, 80, 317-323.	2.5	69
94	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 203-210.	3.0	69
95	Differentiating ischemic from hemorrhagic stroke using plasma biomarkers: The S100B/RAGE pathway. Journal of Proteomics, 2012, 75, 4758-4765.	2.4	68
96	Interleukin-1β Augments Angiogenic Responses of Murine Endothelial Progenitor Cells <i>in Vitro</i> . Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 933-943.	4.3	66
97	Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke. Stroke, 2010, 41, 1528-1535.	2.0	66
98	Endothelial Progenitor Cell Secretome and Oligovascular Repair in a Mouse Model of Prolonged Cerebral Hypoperfusion. Stroke, 2018, 49, 1003-1010.	2.0	66
99	Principles of precision medicine in stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 54-61.	1.9	64
100	Antibodies Preventing the Interaction of Tissue-Type Plasminogen Activator With N-Methyl- <scp>d</scp> -Aspartate Receptors Reduce Stroke Damages and Extend the Therapeutic Window of Thrombolysis. Stroke, 2011, 42, 2315-2322.	2.0	63
101	Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis. Stroke, 2021, 52, 543-551.	2.0	63
102	Systematic Review of Cysteine-Sparing NOTCH3 Missense Mutations in Patients with Clinical Suspicion of CADASIL. International Journal of Molecular Sciences, 2017, 18, 1964.	4.1	62
103	Matrix Metalloproteinase-13 is Activated and is found in the Nucleus of Neural Cells after Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 398-410.	4.3	61
104	Arterial Stiffness Is Associated With Basal Ganglia Enlarged Perivascular Spaces and Cerebral Small Vessel Disease Load. Stroke, 2018, 49, 1279-1281.	2.0	61
105	Safety Profile of Tissue Plasminogen Activator Treatment Among Stroke Patients Carrying a Common Polymorphism (C-1562T) in the Promoter Region of the Matrix Metalloproteinase-9 Gene. Stroke, 2003, 34, 2851-2855.	2.0	60
106	Reduction of Tissue Plasminogen Activator-Induced Matrix Metalloproteinase-9 by Simvastatin in Astrocytes. Stroke, 2006, 37, 1910-1912.	2.0	60
107	Brain Perihematoma Genomic Profile Following Spontaneous Human Intracerebral Hemorrhage. PLoS ONE, 2011, 6, e16750.	2.5	60
108	Potential Role of Blood Biomarkers in the Management of Nontraumatic Intracerebral Hemorrhage. Cerebrovascular Diseases, 2014, 38, 395-409.	1.7	59

Joan Montaner

#	Article	IF	CITATIONS
109	Plasma S100B Level After Acute Spontaneous Intracerebral Hemorrhage. Stroke, 2006, 37, 2837-2839.	2.0	58
110	Combination of Thrombolysis and Statins in Acute Stroke Is Safe. Stroke, 2016, 47, 2870-2873.	2.0	58
111	<i>COL4A2</i> is associated with lacunar ischemic stroke and deep ICH. Neurology, 2017, 89, 1829-1839.	1.1	58
112	Rapid synthesis of water-dispersible superparamagnetic iron oxide nanoparticles by a microwave-assisted route for safe labeling of endothelial progenitor cells. Acta Biomaterialia, 2014, 10, 3775-3785.	8.3	57
113	Charge effect of a liposomal delivery system encapsulating simvastatin to treat experimental ischemic stroke in rats. International Journal of Nanomedicine, 2016, Volume 11, 3035-3048.	6.7	56
114	Distal Occlusion of the Middle Cerebral Artery in Mice: Are We Ready to Assess Long-Term Functional Outcome?. Translational Stroke Research, 2013, 4, 297-307.	4.2	55
115	Cognitive Impact of Cerebral Small Vessel Disease Changes in Patients With Hypertension. Hypertension, 2019, 73, 342-349.	2.7	55
116	Natalizumab in acute ischemic stroke (ACTION II). Neurology, 2020, 95, e1091-e1104.	1.1	55
117	Pretreatment Hemostatic Markers of Symptomatic Intracerebral Hemorrhage in Patients Treated With Tissue Plasminogen Activator. Stroke, 2006, 37, 996-999.	2.0	54
118	Role of Fibrinogen Levels and Factor XIII V34L Polymorphism in Thrombolytic Therapy in Stroke Patients. Stroke, 2006, 37, 2288-2293.	2.0	54
119	Association of a Genetic Variant in the <i>ALOX5AP</i> with Higher Risk of Ischemic Stroke: A Case-Control, Meta-Analysis and Functional Study. Cerebrovascular Diseases, 2010, 29, 528-537.	1.7	54
120	Do Bubble Characteristics Affect Recanalization in Stroke Patients Treated with Microbubble-Enhanced Sonothrombolysis?. Ultrasound in Medicine and Biology, 2008, 34, 1573-1577.	1.5	53
121	In vitro angiogenic performance and in vivo brain targeting of magnetized endothelial progenitor cells for neurorepair therapies. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 225-234.	3.3	53
122	Angiogenesis in Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 92-97.	2.0	52
123	SARS-CoV-2 and Stroke Characteristics. Stroke, 2021, 52, e117-e130.	2.0	51
124	Genetics of stroke: a review of recent advances. Expert Review of Molecular Diagnostics, 2008, 8, 495-513.	3.1	49
125	Automated quantification of cerebral edema following hemispheric infarction: Application of a machine-learning algorithm to evaluate CSF shifts on serial head CTs. NeuroImage: Clinical, 2016, 12, 673-680.	2.7	49
126	Plasmatic retinolâ€binding protein 4 and glial fibrillary acidic protein as biomarkers to differentiate ischemic stroke and intracerebral hemorrhage. Journal of Neurochemistry, 2016, 136, 416-424.	3.9	49

#	Article	IF	CITATIONS
127	<i>PATJ</i> Low Frequency Variants Are Associated With Worse Ischemic Stroke Functional Outcome. Circulation Research, 2019, 124, 114-120.	4.5	49
128	Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. Neurology, 2018, 90, e995-e1004.	1.1	48
129	Therapeutic hypothermia for acute ischaemic stroke. Results of a European multicentre, randomised, phase III clinical trial. European Stroke Journal, 2019, 4, 254-262.	5.5	48
130	Silent Myocardial Ischemia in Patients With Symptomatic Intracranial Atherosclerosis. Stroke, 2005, 36, 1201-1206.	2.0	46
131	Speed of tPA-Induced Clot Lysis Predicts DWI Lesion Evolution in Acute Stroke. Stroke, 2007, 38, 955-960.	2.0	46
132	Global DNA Methylation of Ischemic Stroke Subtypes. PLoS ONE, 2014, 9, e96543.	2.5	46
133	<i>TRAF3</i> Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke, 2016, 47, 1180-1186.	2.0	46
134	Yield of atrial fibrillation detection with Textile Wearable Holter from the acute phase of stroke: Pilot study of Crypto-AF registry. International Journal of Cardiology, 2018, 251, 45-50.	1.7	46
135	European Research Priorities for Intracerebral Haemorrhage. Cerebrovascular Diseases, 2011, 32, 409-419.	1.7	45
136	Modulation of Amyloid-β1–40 Transport by ApoA1 and ApoJ Across an in vitro Model of the Blood-Brain Barrier. Journal of Alzheimer's Disease, 2016, 53, 677-691.	2.6	45
137	Endothelial progenitor cells and revascularization following stroke. Brain Research, 2015, 1623, 150-159.	2.2	44
138	Platelet function testing in transient ischaemic attack and ischaemic stroke: A comprehensive systematic review of the literature. Platelets, 2015, 26, 402-412.	2.3	44
139	The Proteome of Human Brain After Ischemic Stroke. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1105-1115.	1.7	43
140	Matrix Metalloproteinase 2 (MMP-2) Degrades Soluble Vasculotropic Amyloid-β E22Q and L34V Mutants, Delaying Their Toxicity for Human Brain Microvascular Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 27144-27158.	3.4	43
141	Intra-Arterial Bone Marrow Mononuclear Cells (BM-MNCS) Transplantation in Acute Ischemic Stroke (IBiS Trial): Protocol of a Phase II, Randomized, Dose-Finding, Controlled Multicenter Trial. International Journal of Stroke, 2015, 10, 1149-1152.	5.9	43
142	Matrix metalloproteinases and ADAMs in stroke. Cellular and Molecular Life Sciences, 2019, 76, 3117-3140.	5.4	43
143	Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity. JAMA Neurology, 2019, 76, 480.	9.0	43
144	Recommendations for Clinical Trials in ICH. Stroke, 2020, 51, 1333-1338.	2.0	42

#	Article	IF	CITATIONS
145	Plasma β-Amyloid Levels in Cerebral Amyloid Angiopathy-Associated Hemorrhagic Stroke. Neurodegenerative Diseases, 2012, 10, 320-323.	1.4	41
146	VAP-1/SSAO Plasma Activity and Brain Expression in Human Hemorrhagic Stroke. Cerebrovascular Diseases, 2012, 33, 55-63.	1.7	41
147	Investigating silent strokes in hypertensives: a magnetic resonance imaging study (ISSYS): rationale and protocol design. BMC Neurology, 2013, 13, 130.	1.8	41
148	STAT-Dependent Upregulation of 12/15-Lipoxygenase Contributes to Neuronal Injury after Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 2043-2051.	4.3	40
149	Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study. European Heart Journal, 2021, 42, 2186-2196.	2.2	40
150	Fas System Activation in Perihematomal Areas After Spontaneous Intracerebral Hemorrhage. Stroke, 2008, 39, 1730-1734.	2.0	39
151	Burden of Risk Alleles for Hypertension Increases Risk of Intracerebral Hemorrhage. Stroke, 2012, 43, 2877-2883.	2.0	39
152	A predictive clinical–genetic model of tissue plasminogen activator response in acute ischemic stroke. Annals of Neurology, 2012, 72, 716-729.	5.3	39
153	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 710-717.	4.3	39
154	Clinical risk scores for predicting stroke-associated pneumonia: A systematic review. European Stroke Journal, 2016, 1, 76-84.	5.5	39
155	Early measurement of interleukin-10 predicts the absence of CT scan lesions in mild traumatic brain injury. PLoS ONE, 2018, 13, e0193278.	2.5	39
156	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	3.5	38
157	A new method for focal transient cerebral ischaemia by distal compression of the middle cerebral artery. Neuropathology and Applied Neurobiology, 2012, 38, 617-627.	3.2	38
158	Absence of Usefulness of ABCD Score in the Early Risk of Stroke of Transient Ischemic Attack Patients. Stroke, 2007, 38, 855-856.	2.0	36
159	Design of a Prospective Multi-National CLOTBUST Collaboration on Reperfusion Therapies for Stroke. International Journal of Stroke, 2008, 3, 66-72.	5.9	36
160	Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain, 2009, 132, 2219-2230.	7.6	36
161	Lipoprotein-Associated Phospholipase A ₂ Activity Is Associated with Large-Artery Atherosclerotic Etiology and Recurrent Stroke in TIA Patients. Cerebrovascular Diseases, 2012, 33, 150-158.	1.7	36
162	The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke. Frontiers in Neurology, 2017, 8, 153.	2.4	36

#	Article	IF	CITATIONS
163	Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome. Stroke, 2021, 52, 132-141.	2.0	36
164	Intra-Arterial Bone Marrow Mononuclear Cell Transplantation Correlates with GM-CSF, PDGF-BB, and MMP-2 Serum Levels in Stroke Patients: Results from a Clinical Trial. Cell Transplantation, 2014, 23, 57-64.	2.5	35
165	Antiâ€inflammatory effects of ADAMTSâ€4 in a mouse model of ischemic stroke. Glia, 2016, 64, 1492-1507.	4.9	35
166	Predictors of Restenosis Following Carotid Angioplasty and Stenting. Stroke, 2016, 47, 2144-2147.	2.0	35
167	New QuinolyInitrones for Stroke Therapy: Antioxidant and Neuroprotective (<i>Z</i>)- <i>N</i> - <i>tert</i> -Butyl-1-(2-chloro-6-methoxyquinolin-3-yl)methanimine Oxide as a New Lead-Compound for Ischemic Stroke Treatment. Journal of Medicinal Chemistry, 2019, 62, 2184-2201.	6.4	35
168	Neuronal TIMPâ€1 release accompanies astrocytic MMPâ€9 secretion and enhances astrocyte proliferation induced by βâ€amyloid 25–35 fragment. Journal of Neuroscience Research, 2009, 87, 2115-2125.	2.9	34
169	Cerebral ischaemia and matrix metalloproteinaseâ€9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells. Journal of Cellular and Molecular Medicine, 2013, 17, 1543-1553.	3.6	34
170	H-FABP: A new biomarker to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS ONE, 2017, 12, e0175572.	2.5	34
171	Blood Biomarkers to Differentiate Ischemic and Hemorrhagic Strokes. Neurology, 2021, 96, e1928-e1939.	1.1	34
172	Common Variants Within Oxidative Phosphorylation Genes Influence Risk of Ischemic Stroke and Intracerebral Hemorrhage. Stroke, 2013, 44, 612-619.	2.0	33
173	Genetic variants inCETPincrease risk of intracerebral hemorrhage. Annals of Neurology, 2016, 80, 730-740.	5.3	33
174	Combining H-FABP and GFAP increases the capacity to differentiate between CT-positive and CT-negative patients with mild traumatic brain injury. PLoS ONE, 2018, 13, e0200394.	2.5	33
175	Detection of plasma MMP-9 within minutes. Unveiling some of the clues to develop fast and simple electrochemical magneto-immunosensors. Biosensors and Bioelectronics, 2018, 115, 45-52.	10.1	32
176	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. Clinical Pharmacology and Therapeutics, 2020, 108, 1067-1077.	4.7	32
177	Comparison of the impact of atrial fibrillation on the risk of early death after stroke in women versus men. Journal of Neurology, 2006, 253, 1484-1489.	3.6	31
178	Predictors of Tissue-Type Plasminogen Activator Nonresponders According to Location of Vessel Occlusion. Stroke, 2012, 43, 417-421.	2.0	31
179	Impaired Vascular Remodeling after Endothelial Progenitor Cell Transplantation in MMP9-Deficient Mice Suffering Cortical Cerebral Ischemia. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1547-1551.	4.3	31
180	Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy. Thrombosis and Haemostasis, 2016, 115, 1129-1137.	3.4	31

#	Article	IF	CITATIONS
181	Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis. Scientific Reports, 2017, 7, 14637.	3.3	31
182	Using magnetic beads and signal amplifiers to produce short and simple immunoassays: Application to MMP-9 detection in plasma samples. Analytica Chimica Acta, 2018, 999, 144-154.	5.4	31
183	Microbiological Etiologies of Pneumonia Complicating Stroke. Stroke, 2018, 49, 1602-1609.	2.0	31
184	Glial fibrillary acidic protein for the early diagnosis of intracerebral hemorrhage: Systematic review and meta-analysis of diagnostic test accuracy. International Journal of Stroke, 2019, 14, 390-399.	5.9	31
185	Prevalence and Associated Factors of Silent Brain Infarcts in a Mediterranean Cohort of Hypertensives. Hypertension, 2014, 64, 658-663.	2.7	30
186	Citicoline in preâ€clinical animal models of stroke: a metaâ€analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. Journal of Neurochemistry, 2012, 123, 217-225.	3.9	29
187	Intravenous treatment with human recombinant ApoA-I Milano reduces beta amyloid cerebral deposition in the APP23-transgenic mouse model of Alzheimer's disease. Neurobiology of Aging, 2017, 60, 116-128.	3.1	29
188	Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. Alzheimer's Research and Therapy, 2019, 11, 42.	6.2	29
189	<i>IL1B</i> and <i>VWF</i> Variants Are Associated With Fibrinolytic Early Recanalization in Patients With Ischemic Stroke. Stroke, 2012, 43, 2659-2665.	2.0	28
190	From brain to blood: New biomarkers for ischemic stroke prognosis. Journal of Proteomics, 2013, 94, 138-148.	2.4	28
191	<i>PPM1A</i> Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. Stroke, 2016, 47, 1926-1929.	2.0	28
192	Blood biomarkers for the diagnosis and differentiation of stroke: A systematic review and meta-analysis. International Journal of Stroke, 2020, 15, 704-721.	5.9	28
193	Increasing Dose of Autologous Bone Marrow Mononuclear Cells Transplantation Is Related to Stroke Outcome: Results from a Pooled Analysis of Two Clinical Trials. Stem Cells International, 2016, 2016, 1-8.	2.5	27
194	Neuroprotective Effects of Diets Containing Olive Oil and DHA/EPA in a Mouse Model of Cerebral Ischemia. Nutrients, 2019, 11, 1109.	4.1	27
195	Blood biomarkers predictive of epilepsy after an acute stroke event. Epilepsia, 2020, 61, 2244-2253.	5.1	27
196	Blood Glutathione S-Transferase-Ï€ as a Time Indicator of Stroke Onset. PLoS ONE, 2012, 7, e43830.	2.5	27
197	Clinical Variables and Genetic Risk Factors Associated with the Acute Outcome of Ischemic Stroke: A Systematic Review. Journal of Stroke, 2019, 21, 276-289.	3.2	27
198	CholesteroNitrones for Stroke. Journal of Medicinal Chemistry, 2015, 58, 6704-6709.	6.4	26

#	Article	IF	CITATIONS
199	Neuroprotective diets for stroke. Neurochemistry International, 2017, 107, 4-10.	3.8	26
200	Blood markers of inflammation and endothelial dysfunction in cardioembolic stroke: systematic review and meta-analysis. Biomarkers, 2017, 22, 200-209.	1.9	26
201	External Validation of the ISAN, A2DS2, and AIS-APS Scores for Predicting Stroke-Associated Pneumonia. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 673-676.	1.6	26
202	Single Cell Immuno-Laser Microdissection Coupled to Label-Free Proteomics to Reveal the Proteotypes of Human Brain Cells After Ischemia. Molecular and Cellular Proteomics, 2018, 17, 175-189.	3.8	26
203	<i>17p12</i> Influences Hematoma Volume and Outcome in Spontaneous Intracerebral Hemorrhage. Stroke, 2018, 49, 1618-1625.	2.0	26
204	Brain proteomics identifies potential simvastatin targets in acute phase of stroke in a rat embolic model. Journal of Neurochemistry, 2014, 130, 301-312.	3.9	25
205	Circulating cell-free DNA is a predictor of short-term neurological outcome in stroke patients treated with intravenous thrombolysis. Journal of Circulating Biomarkers, 2016, 5, 184945441666879.	1.3	25
206	Matrix metalloproteinase-13 participates in neuroprotection and neurorepair after cerebral ischemia in mice. Neurobiology of Disease, 2016, 91, 236-246.	4.4	25
207	Predicting Atrial Fibrillation with High Risk of Embolization with Atrial Strain and NT-proBNP. Translational Stroke Research, 2021, 12, 735-741.	4.2	25
208	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	2.6	25
209	Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	25
210	D-Dimer as Predictor of Large Vessel Occlusion in Acute Ischemic Stroke. Stroke, 2021, 52, 852-858.	2.0	25
211	Lipoprotein-associated phospholipase A2 testing usefulness among patients with symptomatic intracranial atherosclerotic disease. Atherosclerosis, 2011, 218, 181-187.	0.8	24
212	Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Research, 2011, 1373, 211-220.	2.2	24
213	DNA Isolation Method Is a Source of Global DNA Methylation Variability Measured with LUMA. Experimental Analysis and a Systematic Review. PLoS ONE, 2013, 8, e60750.	2.5	24
214	The impact of post-stroke complications on in-hospital mortality depends on stroke severity. European Stroke Journal, 2017, 2, 54-63.	5.5	24
215	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	2.7	24
216	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. BMJ Open Diabetes Research and Care, 2019, 7, e000845.	2.8	24

#	Article	IF	CITATIONS
217	ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters, 2006, 398, 167-171.	2.1	23
218	Endogenous Activated Protein C Predicts Hemorrhagic Transformation and Mortality after Tissue Plasminogen Activator Treatment in Stroke Patients. Cerebrovascular Diseases, 2009, 28, 143-150.	1.7	23
219	Molecular damage in <scp>F</scp> abry disease: Characterization and prediction of alphaâ€galactosidase <scp>A</scp> pathological mutations. Proteins: Structure, Function and Bioinformatics, 2015, 83, 91-104.	2.6	23
220	Câ€reactive protein in the detection of postâ€stroke infections: systematic review and individual participant data analysis. Journal of Neurochemistry, 2017, 141, 305-314.	3.9	23
221	GRECOS Project (Genotyping Recurrence Risk of Stroke). Stroke, 2017, 48, 1147-1153.	2.0	23
222	Quinolinyl Nitrone RP19 Induces Neuroprotection after Transient Brain Ischemia. ACS Chemical Neuroscience, 2017, 8, 2202-2213.	3.5	23
223	Profiling and identification of new proteins involved in brain ischemia using MALDI-imaging-mass-spectrometry. Journal of Proteomics, 2017, 152, 243-253.	2.4	23
224	C-Reactive Protein Gene C1444T Polymorphism and Risk of Recurrent Ischemic Events in Patients with Symptomatic Intracranial Atherostenoses. Cerebrovascular Diseases, 2009, 28, 95-102.	1.7	22
225	KCNK17 genetic variants in ischemic stroke. Atherosclerosis, 2010, 208, 203-209.	0.8	22
226	ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy. Neurobiology of Aging, 2011, 32, 551.e13-551.e22.	3.1	22
227	Cardioembolic Stroke Diagnosis Using Blood Biomarkers. Current Cardiology Reviews, 2014, 9, 340-352.	1.5	22
228	Recommendations From the International Stroke Genetics Consortium, Part 1. Stroke, 2015, 46, 279-284.	2.0	22
229	Obstructive sleep apnea and silent cerebral infarction in hypertensive individuals. Journal of Sleep Research, 2018, 27, 232-239.	3.2	22
230	Diagnostic accuracy of noncontrast CT imaging markers in cerebral venous thrombosis. Neurology, 2019, 92, e841-e851.	1.1	22
231	Antibiotic treatment for pneumonia complicating stroke: Recommendations from the pneumonia in stroke consensus (PISCES) group. European Stroke Journal, 2019, 4, 318-328.	5.5	22
232	Identification of 20 novel loci associated with ischaemic stroke. Epigenome-wide association study. Epigenetics, 2020, 15, 988-997.	2.7	22
233	External Validation of Five Scores to Predict Stroke-Associated Pneumonia and the Role of Selected Blood Biomarkers. Stroke, 2021, 52, 325-330.	2.0	22
234	Stroke Biomarkers: Can They Help Us to Guide Stroke Thrombolysis?. Drug News and Perspectives, 2006, 19, 523.	1.5	22

#	Article	IF	CITATIONS
235	Treatment with statins in the acute phase of ischemic stroke. Expert Review of Neurotherapeutics, 2005, 5, 211-221.	2.8	21
236	CADASIL management or what to do when there is little one can do. Expert Review of Neurotherapeutics, 2009, 9, 197-210.	2.8	20
237	ApoA1, ApoJ and ApoE Plasma Levels and Genotype Frequencies in Cerebral Amyloid Angiopathy. NeuroMolecular Medicine, 2016, 18, 99-108.	3.4	20
238	Importance of Angiogenin and Endothelial Progenitor Cells After Rehabilitation Both in Ischemic Stroke Patients and in a Mouse Model of Cerebral Ischemia. Frontiers in Neurology, 2018, 9, 508.	2.4	20
239	A Mouse Brain-based Multi-omics Integrative Approach Reveals Potential Blood Biomarkers for Ischemic Stroke. Molecular and Cellular Proteomics, 2020, 19, 1921-1936.	3.8	20
240	Lower concentrations of thrombin-antithrombin complex (TAT) correlate to higher recanalisation rates among ischaemic stroke patients treated with t-PA. Thrombosis and Haemostasis, 2009, 102, 759-764.	3.4	19
241	Stroke with polyvascular atherothrombotic disease. Atherosclerosis, 2010, 208, 587-592.	0.8	18
242	The angiogenic gene profile of circulating endothelial progenitor cells from ischemic stroke patients. Vascular Cell, 2013, 5, 3.	0.2	18
243	Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics, 2013, 14, 495-504.	1.3	18
244	N-terminal pro-brain natriuretic peptide and subclinical brain small vessel disease. Neurology, 2016, 87, 2533-2539.	1.1	18
245	Selection bias in clinical stroke trials depending on ability to consent. BMC Neurology, 2017, 17, 206.	1.8	18
246	Causal Effect of MMP-1 (Matrix Metalloproteinase-1), MMP-8, and MMP-12 Levels on Ischemic Stroke. Stroke, 2021, 52, e316-e320.	2.0	18
247	Role of Endogenous Granulocyte-Macrophage Colony Stimulating Factor Following Stroke and Relationship to Neurological Outcome. Current Neurovascular Research, 2009, 6, 246-251.	1.1	18
248	Targeting p35/Cdk5 Signalling via CIP-Peptide Promotes Angiogenesis in Hypoxia. PLoS ONE, 2013, 8, e75538.	2.5	17
249	DNA methylation levels are highly correlated between pooled samples and averaged values when analysed using the Infinium HumanMethylation450 BeadChip array. Clinical Epigenetics, 2015, 7, 78.	4.1	17
250	Microalbuminuria and the Combination of MRI Markers of Cerebral Small Vessel Disease. Cerebrovascular Diseases, 2016, 42, 66-72.	1.7	17
251	Plasma Matrix Metalloproteinases in Patients With Stroke During Intensive Rehabilitation Therapy. Archives of Physical Medicine and Rehabilitation, 2016, 97, 1832-1840.	0.9	17
252	Characterization of secretomes from a human blood brain barrier endothelial cells in-vitro model after ischemia by stable isotope labeling with aminoacids in cell culture (SILAC). Journal of Proteomics, 2016, 133, 100-112.	2.4	17

Joan Montaner

#	Article	IF	CITATIONS
253	Antibiotic Class and Outcome in Post-stroke Infections: An Individual Participant Data Pooled Analysis of VISTA-Acute. Frontiers in Neurology, 2019, 10, 504.	2.4	17
254	Clinical Predictors of Hyperperfusion Syndrome Following Carotid Stenting. JACC: Cardiovascular Interventions, 2019, 12, 873-882.	2.9	17
255	Overlap in the Genetic Architecture of Stroke Risk, Early Neurological Changes, and Cardiovascular Risk Factors. Stroke, 2019, 50, 1339-1345.	2.0	17
256	Correlation of blood biomarkers with early-onset seizures after an acute stroke event. Epilepsy and Behavior, 2020, 104, 106549.	1.7	17
257	Blood Biomarker Panels for the Early Prediction of Strokeâ€Associated Complications. Journal of the American Heart Association, 2021, 10, e018946.	3.7	17
258	Role of microglial and endothelial CD36 in post-ischemic inflammasome activation and interleukin-1β-induced endothelial activation. Brain, Behavior, and Immunity, 2021, 95, 489-501.	4.1	17
259	<i>CD40</i> -1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics, 2010, 11, 763-772.	1.3	16
260	Advanced neuroprotection for brain ischemia: an alternative approach to minimize stroke damage. Expert Opinion on Investigational Drugs, 2015, 24, 1137-1142.	4.1	16
261	Rehabilitation Profiles of Older Adult Stroke Survivors Admitted to Intermediate Care Units: A Multi-Centre Study. PLoS ONE, 2016, 11, e0166304.	2.5	16
262	Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome. Cerebrovascular Diseases, 2016, 42, 404-414.	1.7	16
263	Sepsis biomarkers reprofiling to predict stroke-associated infections. Journal of Neuroimmunology, 2017, 312, 19-23.	2.3	16
264	SAA (Serum Amyloid A). Stroke, 2020, 51, 3523-3530.	2.0	16
265	Platelet function/reactivity testing and prediction of risk of recurrent vascular events and outcomes after TIA or ischaemic stroke: systematic review and meta-analysis. Journal of Neurology, 2020, 267, 3021-3037.	3.6	16
266	Blood Biomarkers in Cardioembolic Stroke. Current Cardiology Reviews, 2010, 6, 194-201.	1.5	16
267	Genetics of intracerebral haemorrhage: a tsunami effect of APOE ɛ2 genotype on brain bleeding size?. Lancet Neurology, The, 2011, 10, 673-675.	10.2	15
268	Immunological Biomarkers Improve the Accuracy of Clinical Risk Models of Infection in the Acute Phase of Ischemic Stroke. Cerebrovascular Diseases, 2013, 35, 220-227.	1.7	15
269	Role of betaâ€defensin 2 and interleukinâ€4 receptor as stroke outcome biomarkers. Journal of Neurochemistry, 2014, 129, 463-472.	3.9	15
270	New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator. Cardiovascular Research, 2017, 113, 1219-1229.	3.8	15

#	Article	IF	CITATIONS
271	Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome. Brain Communications, 2020, 2, fcaa078.	3.3	15
272	Multi-ancestry GWAS reveals excitotoxicity associated with outcome after ischaemic stroke. Brain, 2022, 145, 2394-2406.	7.6	15
273	Cholesterol Measured Before Stroke Thrombolysis Is Not Associated With Tissue Plasminogen Activator–Related Hemorrhagic Transformation. Stroke, 2008, 39, e6.	2.0	14
274	Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting. Atherosclerosis, 2012, 220, 532-536.	0.8	14
275	Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. Expert Review of Neurotherapeutics, 2014, 14, 1391-1403.	2.8	14
276	NURR1 Involvement in Recombinant Tissue-Type Plasminogen Activator Treatment Complications After Ischemic Stroke. Stroke, 2015, 46, 477-484.	2.0	14
277	High daytime and nighttime ambulatory pulse pressure predict poor cognitive function and mild cognitive impairment in hypertensive individuals. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 253-263.	4.3	14
278	Using polyHRP to produce simplified immunoassays and electrochemical immunosensors. Application to MMP-9 detection in plasma and uterine aspirates. Sensors and Actuators B: Chemical, 2018, 269, 377-384.	7.8	14
279	Cardioembolic Ischemic Stroke Gene Expression Fingerprint in Blood: a Systematic Review and Verification Analysis. Translational Stroke Research, 2020, 11, 326-336.	4.2	14
280	Statin use before and after acute ischemic stroke onset improves neurological outcome. Expert Review of Cardiovascular Therapy, 2009, 7, 1219-1230.	1.5	13
281	Role of the MMP9 Gene in Hemorrhagic Transformations After Tissue-Type Plasminogen Activator Treatment in Stroke Patients. Stroke, 2012, 43, 1398-1400.	2.0	13
282	Factor seven activating protease (FSAP) predicts response to intravenous thrombolysis in acute ischemic stroke. International Journal of Stroke, 2016, 11, 646-655.	5.9	13
283	Natalizumab: a new therapy for acute ischemic stroke?. Expert Review of Neurotherapeutics, 2016, 16, 1013-1021.	2.8	13
284	Paper microfluidics on screen-printed electrodes for simple electrochemical magneto-immunosensor performance. Sensors and Actuators B: Chemical, 2019, 298, 126897.	7.8	13
285	Genome-Wide Association Study of White Blood Cell Counts in Patients With Ischemic Stroke. Stroke, 2019, 50, 3618-3621.	2.0	13
286	Statin Therapy Should Not be Discontinued in Patients With Intracerebral Hemorrhage. Stroke, 2013, 44, 2060-2061.	2.0	12
287	Antiplatelet effects of clopidogrel dose adjustment (75Âmg/d vs 150Âmg/d) after carotid stenting. Journal of Vascular Surgery, 2014, 60, 428-435.	1.1	12
288	Nano-zymography Using Laser-Scanning Confocal Microscopy Unmasks Proteolytic Activity of Cell-Derived Microparticles. Theranostics, 2016, 6, 610-626.	10.0	12

#	Article	IF	CITATIONS
289	Genetic variants influencing elevated myeloperoxidase levels increase risk of stroke. Brain, 2017, 140, 2663-2672.	7.6	12
290	Biomarkers predictive value for early diagnosis of Strokeâ€Associated Pneumonia. Annals of Clinical and Translational Neurology, 2019, 6, 1882-1887.	3.7	12
291	Integrative Multi-omics Analysis to Characterize Human Brain Ischemia. Molecular Neurobiology, 2021, 58, 4107-4121.	4.0	12
292	Admission troponin-I predicts subsequent cardiac complications and mortality in acute stroke patients. European Stroke Journal, 2016, 1, 205-212.	5.5	11
293	TNF-R1 Correlates with Cerebral Perfusion and Acute Ischemia Following Subarachnoid Hemorrhage. Neurocritical Care, 2020, 33, 679-687.	2.4	11
294	Ubiquitin Fusion Degradation Protein 1 as a Blood Marker for the Early Diagnosis of Ischemic Stroke. Biomarker Insights, 2007, 2, 117727190700200.	2.5	10
295	Combining Statins with Tissue Plasminogen Activator Treatment After Experimental and Human Stroke: A Safety Study on Hemorrhagic Transformation. CNS Neuroscience and Therapeutics, 2013, 19, 863-870.	3.9	10
296	Prognostic Value of Plasma Chitotriosidase Activity in Acute Stroke Patients. International Journal of Stroke, 2014, 9, 910-916.	5.9	10
297	Fluorescent Molecular Peroxidation Products. Stroke, 2014, 45, 432-437.	2.0	10
298	Role of lipoprotein-associated phospholipase A2 activity for the prediction of silent brain infarcts in women. Atherosclerosis, 2014, 237, 811-815.	0.8	10
299	Simvastatin blocks soluble SSAO/VAP-1 release in experimental models of cerebral ischemia: Possible benefits for stroke-induced inflammation control. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 542-553.	3.8	10
300	Validation of a clinical-genetics score to predict hemorrhagic transformations after rtPA. Neurology, 2019, 93, e851-e863.	1.1	10
301	N-Terminal Pro B-Type Natriuretic Peptide's Usefulness for Paroxysmal Atrial Fibrillation Detection Among Populations Carrying Cardiovascular Risk Factors. Frontiers in Neurology, 2019, 10, 1226.	2.4	10
302	Single nucleotide variations in <i>ZBTB46</i> are associated with post-thrombolytic parenchymal haematoma. Brain, 2021, 144, 2416-2426.	7.6	10
303	Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis. Journal of Investigative Medicine, 2020, 68, 1379-1385.	1.6	10
304	Reperfusion Therapy for Acute Stroke Improves Outcome by Decreasing Neuroinflammation. Translational Stroke Research, 2010, 1, 261-267.	4.2	9
305	An Inflammatory Polymorphisms Risk Scoring System for the Differentiation of Ischemic Stroke Subtypes. Mediators of Inflammation, 2015, 2015, 1-7.	3.0	9
306	Characterization of a CholesteroNitrone (ISQ-201), a Novel Drug Candidate for the Treatment of Ischemic Stroke. Antioxidants, 2020, 9, 291.	5.1	9

#	Article	IF	CITATIONS
307	Nutraceuticals in the Prevention of Neonatal Hypoxia–Ischemia: A Comprehensive Review of their Neuroprotective Properties, Mechanisms of Action and Future Directions. International Journal of Molecular Sciences, 2021, 22, 2524.	4.1	9
308	Sex Differences by Hospital-Level in Performance and Outcomes of Endovascular Treatment for Acute Ischemic Stroke. Journal of Stroke, 2020, 22, 258-261.	3.2	9
309	Ischemic Stroke Outcome and Early Infection: Its Deleterious Effect Seems to Operate Also among Tissue Plasminogen Activator-Treated Patients. European Neurology, 2011, 65, 82-87.	1.4	8
310	No association of ALOX5AP polymorphisms with risk of MRI-defined brain infarcts. Neurobiology of Aging, 2012, 33, 629.e1-629.e3.	3.1	7
311	Arterial Blood Gas Analysis of Samples Directly Obtained Beyond Cerebral Arterial Occlusion During Endovascular Procedures Predicts Clinical Outcome. Journal of Neuroimaging, 2013, 23, 180-184.	2.0	7
312	Circulating Aquaporin-4 as A biomarker of early neurological improvement in stroke patients: A pilot study. Neuroscience Letters, 2020, 714, 134580.	2.1	7
313	Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain. Scientific Reports, 2020, 10, 2806.	3.3	7
314	Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Biomedicines, 2021, 9, 72.	3.2	7
315	Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke. Life, 2021, 11, 135.	2.4	7
316	Peripheral inflammation preceeding ischemia impairs neuronal survival through mechanisms involving miRâ€127 in aged animals. Aging Cell, 2021, 20, e13287.	6.7	7
317	Editorial Comment—Cooling Matrix Metalloproteinases to Improve Thrombolysis in Acute Ischemic Stroke. Stroke, 2003, 34, 2171-2172.	2.0	6
318	Lysophosphatidylcholine to stratify risk of ischemic stroke in TIA. Neurology, 2015, 84, 17-18.	1.1	6
319	Exome Sequencing and Clot Lysis Experiments Demonstrate the R458C Mutation of the Alpha Chain of Fibrinogen to be Associated with Impaired Fibrinolysis in a Family with Thrombophilia. Journal of Atherosclerosis and Thrombosis, 2016, 23, 431-440.	2.0	6
320	Whole exome sequencing analysis reveals TRPV3 as a risk factor for cardioembolic stroke/subtitle. Thrombosis and Haemostasis, 2016, 116, 1165-1771.	3.4	6
321	Venous and arterial TNF-R1 predicts outcome and complications in acute subarachnoid hemorrhage. Neurocritical Care, 2019, 31, 107-115.	2.4	6
322	Usefulness of TNFR1 as biomarker of intracranial aneurysm in patients with spontaneous subarachnoid hemorrhage. Future Science OA, 2020, 6, FSO431.	1.9	6
323	RP11-362K2.2:RP11-767I20.1 Genetic Variation Is Associated with Post-Reperfusion Therapy Parenchymal Hematoma. A GWAS Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 3137.	2.4	6
324	Clinical Outcomes of Mechanical Thrombectomy in Stroke Tandem Lesions According to Intracranial Occlusion Location. Journal of Stroke, 2021, 23, 124-127.	3.2	6

#	Article	IF	CITATIONS
325	Chest Computed Tomography Findings and Validation of Clinical Criteria of Stroke Associated Pneumonia. Journal of Stroke, 2019, 21, 217-219.	3.2	6
326	Matrix metalloproteinase-9 in fulminant hepatic failure. Hepatology, 2010, 51, 1475-1476.	7.3	5
327	Mild hypothermia protects against oxygen glucose deprivation (OGD)-induced cell death in brain slices from adult mice. Journal of Neural Transmission, 2014, 121, 113-117.	2.8	5
328	Monitoring of Cortical Activity Postreperfusion. A Powerful Tool for Predicting Clinical Response Immediately After Recanalization. Journal of Neuroimaging, 2015, 25, 257-262.	2.0	5
329	Dementia Rating Scale-2 normative data for middle-and older-aged Castilian speaking Spaniards. Clinical Neuropsychologist, 2016, 30, 1443-1456.	2.3	5
330	Galectin-3 is not an outcome biomarker in ischemic stroke. Letter concerning the study †Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. Journal of the Neurological Sciences, 2016, 371, 67-68.	0.6	5
331	Prevalence and risk factors of silent brain infarcts in patients with AF detected by 3T-MRI. Journal of Neurology, 2020, 267, 2675-2682.	3.6	5
332	Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage. Scientific Reports, 2020, 10, 10329.	3.3	5
333	Genome-wide transcriptome study in skin biopsies reveals an association of E2F4 with cadasil and cognitive impairment. Scientific Reports, 2021, 11, 6846.	3.3	5
334	Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage. Journal of Clinical Medicine, 2021, 10, 989.	2.4	5
335	Angiogenin in the Neurogenic Subventricular Zone After Stroke. Frontiers in Neurology, 2021, 12, 662235.	2.4	5
336	B-type natriuretic peptides and mortality after stroke: A systematic review and meta-analysis. Neurology, 2014, 83, 292-293.	1.1	4
337	Identification of Plasma Biomarkers of Human Intracerebral Hemorrhage Subtypes through Microarray Technology. Journal of Stroke and Cerebrovascular Diseases, 2016, 25, 665-671.	1.6	4
338	Safety of Early Carotid Artery Stenting for Symptomatic Stenosis in Daily Practice. European Journal of Vascular and Endovascular Surgery, 2018, 56, 776-782.	1.5	4
339	Circulating microRNA after autologous bone marrow mononuclear cell (BM-MNC) injection in patients with ischemic stroke. Journal of Investigative Medicine, 2020, 68, 807-810.	1.6	4
340	Plasmin Generation Potential and Recanalization in Acute Ischaemic Stroke; an Observational Cohort Study of Stroke Biobank Samples. Frontiers in Neurology, 2020, 11, 589628.	2.4	4
341	<p>Risk of Atrial Fibrillation, Ischemic Stroke and Cognitive Impairment: Study of a Population Cohort ≥65 Years of Age</p> . Vascular Health and Risk Management, 2020, Volume 16, 445-454.	2.3	4
342	DNA methylation of MMPs and TIMPs in atherothrombosis process in carotid plaques and blood tissues. Oncotarget, 2020, 11, 905-912.	1.8	4

#	Article	IF	CITATIONS
343	Mediterranean Diet and Physical Activity Protect from Silent Brain Infarcts in a Cohort of Patients with Atrial Fibrillation. Journal of Stroke, 2019, 21, 353-355.	3.2	4
344	Response to Letter by Topakian et al. Stroke, 2006, 37, 2455-2456.	2.0	3
345	Triflusal and Aspirin Have Different Effects on Inflammatory Biomarkers Measured in Patients with Acute Ischemic Stroke. Cerebrovascular Diseases, 2009, 28, 371-377.	1.7	3
346	Nâ€glycome Profile Levels Relate to Silent Brain Infarcts in a Cohort of Hypertensives. Journal of the American Heart Association, 2015, 4, .	3.7	3
347	The post-stroke clotting battle: ADAMTS13 falls and puts out of control vWF into brain arteries. Journal of the Neurological Sciences, 2015, 348, 1-2.	0.6	3
348	Blood-based biomarkers and stem cell therapy in human stroke: a systematic review. Molecular Biology Reports, 2020, 47, 6247-6258.	2.3	3
349	The Value of Transcranial Doppler Sonography in Hyperperfusion Syndrome after Carotid Artery Stenting: A Nationwide Prospective Study. Journal of Stroke, 2020, 22, 254-257.	3.2	3
350	Nighttime hypoxia affects global cognition, memory, and executive function in community-dwelling individuals with hypertension. Journal of Clinical Sleep Medicine, 2020, 16, 243-250.	2.6	3
351	Application of an Aptamer-Based Proteomics Assay (SOMAscanâ"¢) in Rat Cerebrospinal Fluid. Methods in Molecular Biology, 2019, 2044, 221-231.	0.9	2
352	A panel of biomarkers may successfully predict acute stroke diagnosis. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S117-S117.	4.3	2
353	Rat Middle Cerebral Artery Occlusion Is Not a Suitable Model for the Study of Stroke-Induced Spontaneous Infections. PLoS ONE, 2014, 9, e99169.	2.5	2
354	Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke. Neurotherapeutics, 2022, 19, 513-527.	4.4	2
355	Blood biomarkers for predicting outcome after stroke. Neurology, 2013, 80, 1270-1271.	1.1	1
356	Letter by Riba-Llena et al Regarding Article, "Not Listened or Not Reported Rather Than Silent Stroke― Stroke, 2013, 44, e42.	2.0	1
357	Developing biomarkers for cerebral amyloid angiopathy trials: do potential disease phenotypes hold promise? – Authors' reply. Lancet Neurology, The, 2014, 13, 540.	10.2	1
358	Author response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. Neurology, 2018, 91, 899-899.	1.1	1
359	Lessons learned from proteome analysis of perinatal neurovascular pathologies. Expert Review of Proteomics, 2020, 17, 469-481.	3.0	1
360	Response to Letter by Poppe et al. Stroke, 2008, 39, .	2.0	0

#	Article	IF	CITATIONS
361	Comments on: "Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels as a Biomarker of Acute Intracerebral Hemorrhage― Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2585-2586.	1.6	0
362	Cervical dissection diagnoses increase following endovascular treatments. Journal of International Medical Research, 2020, 48, 030006052090674.	1.0	0
363	Proteins and pathways in atrial fibrillation and atrial cardiomyopathy underlying cryptogenic stroke. IJC Heart and Vasculature, 2022, 39, 100977.	1.1	0